The Journal of Experimental Medicine
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online February 18, 2008
doi:10.1084/jem.2053iti1
The Journal of Experimental Medicine, Vol. 205, No. 3, 505-
The Rockefeller University Press, 0022-1007 $30.00
© 2008 Bashyam
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Bashyam, H.
PubMed
Right arrow Articles by Bashyam, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

IN THIS ISSUE

Regulatory T cell brakes On page 565, Haxhinasto et al. pinpoint the signaling roadblock that stops CD4+ T cells from turning into regulatory T (T reg) cells.

Some T reg cells develop directly from thymic progenitor cells, but others seem to be converts that were once CD4+ T cells. These potentially inflammatory CD4+ T cells turn into immune-suppressing T reg cells when they simultaneously bind antigen and the cytokine TGF-â. The mechanism that flips this switch was unknown.

T reg cells have less PI3K/Akt signaling, which promotes T cell proliferation and survival. The authors now find that the suppression of Akt allows CD4+ T cells to convert. Activated CD4+ T cells that were forced to express Akt were unable to turn on T reg cell–specific genes, including the transcription factor Foxp3. The expression of Akt did not, however, prevent the development of T reg cells from immature thymic T cells that had already turned on Foxp3. Foxp3 levels in these T reg cells were stable, perhaps because the gene becomes fixed in an active state by chromatin modifications.

The perpetual activation of Akt leads to overactive T cells that can trigger autoimmunity and the rejection of transplanted organs. Blockade of Akt signaling using the drug rapamycin can prevent organ rejection. The group found that activated, rapamycin-treated CD4+ T cells expressed Foxp3 and other T reg cell–specific genes, suggesting that the drug helps replace offensive T cells with defensive T reg cells. Formula



Hema Bashyam

hbashyam{at}rockefeller.edu



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Bashyam, H.
PubMed
Right arrow Articles by Bashyam, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS